tbuckley/cabot-search huggingface dataset:
164P A spatially informed transcriptomic model to forecast early resistance to front-line osimertinib in advanced EGFR-mutant NSCLC
Authors: J. Zugazagoitia, G. Ruiz de Garibay, S. Pineda, B. Roch, P. Garrido Lopez, M.D. Isla Casado, I. Vathiotis, C. Aguado, A. Callejo Perez, R. Marse Fabregat, M.R. García Campelo, A. Blasco Cordellat, K. Syrigos, R. Bernabe Caro, O.J. Juan Vidal, E. Conde Gallego, B. Hernando Fuster, G. Macintyre, L.G. Paz-Ares, M. Peressini Álvarez
Journal: Annals of Oncology (2024)
241P Overall survival and updated invasive disease free survival results from the Penelope-B trial investigating palbociclib vs placebo for patients with high-risk HR+/HER2- breast cancer and residual disease after NACT
Authors: S. Loibl, M. Martin Jimenez, H. Bonnefoi, M. Untch, S-B. Kim, H.D. Bear, N.J. McCarthy, K.A. Gelmon, J.Á. García Saenz, C.M. Kelly, T. Reimer, Z. Zhang, M. Toi, H.S. Rugo, M.I. Gnant, A. Makris, M. Debiasi, N. Hirmas, V. Nekljudova, F. Marmé
Journal: Annals of Oncology (2024)
252P Evolution of breast cancer biological subtypes between pre-treatment biopsy and residual disease after neoadjuvant therapy
Authors: K. Pogoda, M. Czopowicz, A. Bak, D. Najmrocka, P. Halasa, H. Pawlik, W. Olszewski, M. Rosinska, A. Niwinska, E. Sarnowska, A. Balata, M. Nagadowska, A. Gorniak, M. Meluch, A. Mlodzinska, M. Wojda, I. Bilska, E. Szombara, Z. Nowecki
Journal: Annals of Oncology (2024)
518MO Update analysis of the randomized phase II study comparing FOLFIRI plus ramucirumab (RAM) versus FOLFOXIRI plus RAM as first-line treatment for patients with metastatic colorectal cancer: WJOG9216G (RECAST)
Authors: K. Yamazaki, Y. Kito, H. Shoji, T. Yamada, T. Tsushima, S. Mitani, K. Shiraishi, H. Yasui, H. Hara, K. Shimozaki, T. Esaki, Y. Shinohara, T. Tsuzuki, S. Kajiura, K. Yoshimura, K. Sakai, K. Nishio, H. Kawakami, S. Hironaka, K. Muro
Journal: Annals of Oncology (2024)
258P Correlation between pathological complete response (pCR) following neoadjuvant docetaxel, carboplatin and trastuzumab (TCH) with or without pertuzumab (TCHP) and PAM50 subtypes in HER2(+) early breast cancer (eBC)
Authors: C. Bueno Muiño, I. Echavarria Diaz-Guardamino, E. Alvarez, Y. Jerez Gilarranz, B. Herrero Lopez, M. Del Monte, T. Massarrah, M. Cebollero, M. Nevado, P.D.L.M. de la Morena Barrio, F. Ayala de la Pena, J.Á. García Saenz, F. Moreno Anton, A. Rodriguez, T. Quintanar Verduguez, D. Malon Gimenez, A.I. Ballesteros Garcia, D. Bañón, S. Lopez-Tarruella Cobo, M. Martin Jimenez
Journal: Annals of Oncology (2024)
270P Dissecting molecular heterogeneity of luminal breast cancers using an ion mobility DIA proteomic approach
Authors: A. Patsouris, H. Lasla, W. Gouraud, F. Guillonneau, V. Verriele, A. Boissard, C. Henry, P. Juin, M. Campone, C. Guette, P. Jezequel
Journal: Annals of Oncology (2024)
412P Exploratory circulating tumor DNA (ctDNA) analysis in HR+/HER2- metastatic breast cancer (mBC) and impact on clinical efficacy with sacituzumab govitecan (SG) in TROPiCS-02
Authors: H.S. Rugo, Y. Zhang, F. Marmé, P. Schmid, J. Cortés, S.M. Tolaney, S. Tang, O.K. Yoon, W. Verret, M. Das Thakur, A. Bardia
Journal: Annals of Oncology (2024)
247P Concurrent versus sequential adjuvant chemoradiotherapy in early-stage breast cancer: A systematic review and meta-analysis
Authors: L.F.C. de Almeida, L.F. Leite, B. McBenedict, R.P.M. Ribeiro, R.C. Barcellos, D.A.S. Toesca, F. Batalini
Journal: Annals of Oncology (2024)
281P Prevalence of HER2-low breast cancer in the GEICAM/2011-06 trial: Agreement in HER2-low classification between standardized immunohistochemistry assays
Authors: F. Rojo, L. Calvo-Martinez, None B. bermejo, L. Bernet, O. Burgués, T. García-Caballero, S. Lopez-Tarruella Cobo, S. Pérez, S. Antolín-Novoa, J.M. Cejalvo, Y. Jerez Gilarranz, C. Morales Estevez, C. Reboredo Rendo, M.T.M. Martinez, J. Herranz, R. Rincón Sánchez, R. Caballero, A. Barnadas, J. De la Haba Rodriguez, M. Martin Jimenez
Journal: Annals of Oncology (2024)
552P Baseline imaging biomarkers to predict outcomes in locally advanced colon cancer (LACC): Data from the FOxTROT international randomised-controlled trial
Authors: J.R. Platt, F. Elliott, P. Quirke, N. West, M.T. Seymour, L. Magill, K. Handley, D. Morton, D. Tolan, J. Seligmann
Journal: Annals of Oncology (2024)
CN11 The challenges of the multidisciplinary work of nurses in the international department at Gustave Roussy Cancer Campus
Authors: Z. Hoyau, T.S. Assi, J. Morel, K. Saleh, C. Chahine, M. Birien, P. Dumarquez, M. Fall, L. Gaceur, C. Garcia, V. Patault, C. Marcos, J. Pongerard, A. Richard, S. Baroux, M. Basset-Lidy, A. Le Cesne
Journal: Annals of Oncology (2024)
514MO The efficacy and safety of ivonescimab with or without ligufalimab in combination with FOLFOXIRI as first-line (1L) treatment for metastatic colorectal cancer (mCRC)
Authors: Y. Deng, H. Liu, L. Xie, J. Zhang, H. Hu, Z. Liu, W. Wang, X. Yu, Z.M. Wang, B. Li, Y. Xia
Journal: Annals of Oncology (2024)
255P Predicting early recurrence in breast cancer patients undergoing neo-adjuvant chemotherapy through MRI-radiomics analysis
Authors: A. D'Angelo, C. Trombadori, E. Boccia, L. Boldrini, D. Giannarelli, G. Franceschini, A. Orlandi, A. Franco, P. Belli, A. Fabi
Journal: Annals of Oncology (2024)
490P Inhibiting glioma cells' migration: Exploring Rho-GTPases as a potential therapeutic target
Authors: I.G. Rolle, P. Del Mestre, I. Manini, S. Mastantuono, M. Skrap, M. Vindigni, C. Di Loreto, A. Magistrato, D. Cesselli
Journal: Annals of Oncology (2024)
242P Clinical outcomes in patients (pts) with HR+/HER2− early breast cancer (EBC) by prior systemic treatment (tx): A subgroup analysis of the NATALEE trial
Authors: N.P. McAndrew, S. Chia, F. Puglisi, A. Bardia, Y. Izarzugaza Peron, C. Schem, B. Xu, F. Le Du, P. Sharma, K. Afenjar, M. Akdere, J.P. Zarate Gonzalez, Y. Chattar, P.A. Fasching
Journal: Annals of Oncology (2024)
272P Modulation of systemic and intratumor metabolism predicts response to fasting-mimicking diet plus chemotherapy in patients with early TNBC
Authors: F. Ligorio, A. Vingiani, T. Torelli, C. Sposetti, L. Provenzano, G. Fotia, A. Belfiore, C. Ferraris, G. Scaperrotta, C. Depretto, A. Martinetti, G.V. Bianchi, G. Capri, S. Folli, S. Minucci, M. Foiani, M. Pagani, F.G.M. De Braud, G. Pruneri, C. Vernieri
Journal: Annals of Oncology (2024)
406P Genomic landscape of endocrine therapy (ET)-resistant BRCA1/2 and PALB2 altered metastatic breast cancer (mBC)
Authors: A. Omar, L. Boscolo Bielo, O. Abdihamid, A. Marra, E. Crimini, C. Belli, P. Zagami, B. Taurelli Salimbeni, N. Fusco, E. Guerini Rocco, C. Criscitiello, S.M. Tolaney, D. Trapani, G. Curigliano
Journal: Annals of Oncology (2024)
259P Relationship between initial tumor burden and the probability of pathological complete response within molecular subtypes of early breast cancer treated with neoadjuvant chemotherapy
Authors: N. Roussot, G. Constantin, I. Desmoulins, C. Kaderbhai, A. Hennequin, S.M. Ilie, D. Mayeur, L. Arnould, A. Bertaut, J-C. Eymard, C. Jouannaud, A.M. Savoye, G. Yazbek, D. Allouache, C. Delcambre, I. Hrab, C. Levy, C. Segura Djezzer, M. Deblock, S. Ladoire
Journal: Annals of Oncology (2024)
377P Phase II study of trifluridine/tipiracil in pre-treated patients with ER-positive, HER2-negative metastatic breast cancer: A Dutch BOOG (2019-01 TIBET) study
Authors: N.A.D. Guchelaar, R.H. Mathijssen, M. De Boer, M.L. van Bekkum, J.B. Heijns, B.E.P.J. Vriens, L.W. Kessels, L.C. Hamming, K.J. Beelen, P. Nieboer, M.M. van Rosmalen, S.M. van den Berg, E. Oomen-de Hoop, R.M. Bijlsma, M.M.E.M. Bos
Journal: Annals of Oncology (2024)
240P Efficacy and safety of ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) in older patients (pts) with HR+/HER2− early breast cancer (EBC) in NATALEE
Authors: M. Untch, D. Yardley, S-A. Im, T. Pluard, L. Hart, J.P. Crown, G. Freyer, C. Zamagni, I. Blancas López-Barajas, F. Parnizari, M. Gao, K. Amin, H. Hu, H.S. Rugo
Journal: Annals of Oncology (2024)
394P Quantitative standardized high sensitivity (HS)-HER2 testing predicts outcomes with trastuzumab deruxtecan (T-DXd) for metastatic breast cancer (MBC)
Authors: P. Tarantino, S.E. Kim, N.N.N. Chan, M.E. Hughes, K. Smith, O.R. D’Amico, R. Kusmick, A.M. Pereslete, L. Alder, C. Anders, S. Morganti, A.C. Garrido-Castro, P. Lorusso, M. Lustberg, S. Sammons, N. Lin, T. Li, N. Tayob, D. Rimm, S.M. Tolaney
Journal: Annals of Oncology (2024)
401P Evaluation of HER2 scoring in breast carcinoma-stained whole slide images
Authors: C. Bossard, Y. Salhi, T. Florian, B. Poulet, B. Cormier, S. Salhi, E. Guinaudeau, L. Lambros, I. Chokri, F. Jossic, J. Chetritt
Journal: Annals of Oncology (2024)
289P Low risk febrile neutropenia: Does combined chemotherapy/immune checkpoint inhibitor necessitate a change in approach?
Authors: J.M.J. Weaver, B. Nagy, S. Raby, F. Coe, T. Knight, D. Bradwell, A. Lewis, C. Wilson, A.C. Armstronh, V. Clay, T. Cooksley
Journal: Annals of Oncology (2024)
288P External validation of an AI-enabled digital test (PreciseDx Breast) to predict breast cancer recurrence within 6-years exhibited good independent performance on a comparable early-stage cohort from the Netherlands
Authors: M.J. Donovan, P. Westenend, C. Meurs, G. Fernandez, J. Zeineh, A. Sainath Madduri, A. Feliz, A. Shtabsky, None X. zhang, B. Veremis, R. Deangel, J.C. Mejias
Journal: Annals of Oncology (2024)
509O Total neoadjuvant treatment (TNT) with non-operative management (NOM) for proficient mismatch repair locally advanced rectal cancer (pMMR LARC): First results of NO-CUT trial
Authors: A. Amatu, M.G. Zampino, F. Bergamo, S. Mosconi, D. Sibio, M. Gerardi, A.A. Prete, F.R. Filippone, G. Ferrari, S. Borin, S. Galuppo, S. Mariano, F.M. Tosi, E.F. Bonazzina, G. Patelli, S. Ghezzi, L. Lazzari, K. Bencardino, A. Sartore Bianchi, S. Siena
Journal: Annals of Oncology (2024)
433TiP Phase III, randomized, open-label TroFuse-010 Study of sacituzumab tirumotecan (sac-TMT) alone and with pembrolizumab vs treatment of physician’s choice chemotherapy (TPC) in patients with HR+/HER2- unresectable locally advanced or metastatic breast cancer (mBC)
Authors: S.M. Tolaney, P. D’Amico, L. Jia, K.M. Hirshfield, F. Cardoso
Journal: Annals of Oncology (2024)
405P HRD biomarkers in blood samples from BRCA1/BRCA2-associated advanced breast cancer (BC) patients (pts)
Authors: V. Serra, H. Domenech, S.J. Pettitt, P. Proszek, F. Pedretti, A. Herencia Ropero, A. Rodriguez Hernandez, A. Suñol, C. Viaplana, J. Domenech Vivo, S. Gutierrez-Enriquez, M. Oliveira, J. Mateo, A. Prat, C.J. Lord, A.N.J. Tutt, A. Llop-Guevara, J. Balmaña
Journal: Annals of Oncology (2024)
506O Evaluation of risk of disease progression in first-line therapy of unresected metastatic colorectal cancer to guide intervals of radiological assessment: An analysis of eleven randomized trials by AIO and GONO
Authors: M.M. Germani, V. Heinemann, D. Rossini, L. Fischer von Weikersthal, F. Morano, K. Heinrich, A. Stahler, F. Bergamo, F. Kaiser, T. Decker, L. Salvatore, L. Weiss, A. Russo, M. Fuchs, A.A. Prete, C. Antoniotti, G. Masi, S. Stintzing, C. Cremolini, D.P. Modest
Journal: Annals of Oncology (2024)
291P Multi-center investigation of a detection model utilizing cfDNA for early-stage breast cancer screening
Authors: C.L. Ni, J. Zhou, Y. Zhu, S. Sun, J. Liu, J. Ding, X. Gu, J. Zhou, J. Chen, J. Huang, Y. Chen, J. Gongsheng, Q. Zhu, W. Xue, Z. Lin
Journal: Annals of Oncology (2024)
234MO Explaining the relationships between age, endocrine therapy persistence and risk of recurrence in hormone-positive early breast cancer: A nationwide cohort study
Authors: E. Dumas, F. Jochum, F. Coussy, A-S. Hamy-Petit, A. Majdling, S. Houzard, C. Le Bihan-Benjamin, F. Reyal, P. Gougis, M.J. Stensrud
Journal: Annals of Oncology (2024)
268P Impact of B cell and plasma cell infiltration on survival in early-stage breast cancer (BC) without recurrence
Authors: L. Angelats, L. Pare Brunet, C. Rubio-Perez, E. Sanfeliu Torres, E. Segui Solis, G. Villacampa, M. Marin, B. Conte, O. Martinez Saez, A. Fernandez-Martinez, W. Buckingham, S. Guedan, H. Heyn, A. Vivancos, J. Parker, P. Villagrasa Gonzalez, C.M. Perou, A. Prat, F. Braso Maristany
Journal: Annals of Oncology (2024)
360P Identification of circulating immune factors as predictive biomarkers of CDK4/6i treatment efficacy in advanced breast cancer
Authors: S. Cabrero-de las Heras, E. Felip Falgas, E. Riveira-Muñoz, M.A. Bergamino, A. Ferrando Diez, I. Teruel-Garcia, M. Romeo Marin, L. Boronat Ruiz, A. Pous, A. Lopez, B. Cirauqui Cirauqui, M. Margeli Vila, E. Ballana
Journal: Annals of Oncology (2024)
415P Comprehensive liquid biopsy characterization of patients with metastatic inflammatory breast cancer
Authors: E. Nicolo, L. Foffano, E. Molteni, L. Gerratana, L. Munoz-Arcos, M.S. Serafini, L. Pontolillo, C. Gianni, N. Bayou, K. Strickland, M. Manai, Y. Zhang, P. D'Amico, A.A. Davis, J. Donahue, H. Liu, W.J. Gradishar, G. Curigliano, C. Reduzzi, M. Cristofanilli
Journal: Annals of Oncology (2024)
428P Key landmarks of male advanced breast cancer: Results of the GEICAM/2016-04 study
Authors: N. Martinez, M.P. Martinez del Prado, C. Hernando Melia, S. Recalde Penabad, A.S. Muñoz, D. Morales Pancorbo, M. Santisteban Eslava, I. Fernandez Perez, S. Del Barco Berron, E. Zamora Adelantado, V. Iranzo, T. Martos Cardenas, E. Martinez de Dueñas, S. Antolín-Novoa, A.L. Guerrero Zotano, R. Ferreira Alonso, C. Esteban Esteban, S. Enrech Frances, A.A. Tejera Hernández, A. Urruticoechea
Journal: Annals of Oncology (2024)
243P Prognosis of patients with hormone receptor-positive/HER2-negative early breast cancer according to monarchE and NATALEE trials risk categories: Patient-level analysis of Mammella InterGruppo (MIG) and Gruppo Italiano Mammella (GIM) randomised trials
Authors: L. Arecco, E. Blondeaux, M. Bruzzone, G. Arpino, C. De Angelis, M. De Laurentiis, R. Caputo, A. Fabi, None V. sanna, S. Gori, F. Puglisi, L. Boni, S. Nardin, I. Giannubilo, M. Perachino, R. Borea, E. Agostinetto, E. de Azambuja, M. Lambertini, L. Del Mastro
Journal: Annals of Oncology (2024)
152P Exploratory biomarker analysis of phase III ASTRUM-004 study: Serplulimab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer
Authors: C. Zhou, Y. Hu, E. Arkania, S. Kilickap, K. Ying, F. Xu, L. Wu, X. Wang, M. Viguro, T. Makharadze, L. Guo, F. Yang, Y. Liu, X. Yang, S. Zhong, Q. Wang, J. Li, Y. Shan, J. Zhu
Journal: Annals of Oncology (2024)
151P Enhanced pharmacodynamic effects upon combination of cibisatamab and FAP-4-1BBL in 3L+ mMSS CRC patients
Authors: I. Melero, T. Tanos, C. Heichinger, I. Davydov, A. Boehnke, N. Kumpesa, C. Ooi, V. Karanikas, M. Cannarile, I. Baraibar Argota, M. Martinez Garcia, V. Moreno Garcia, C. Qvortrup, T.W. Kim, S-H. Beom, M.G. Van Dongen, E. Calvo, M.C. Riesco Martinez, F. Thistlethwaite, V.K. Woodcock
Journal: Annals of Oncology (2024)
121P Comprehensive cancer genome profiling as supportive tool for treatment decision-making in patients with metastatic solid tumors: Real-world evidence-based meta-analysis and nationwide cancer registry data implementation
Authors: I. Zerdes, P. Filis, G. Fountoukidis, A.I. El-Naggar, F. Kalofonou, A. D'Alessio, A. Pouptsis, T. Foukakis, G. Pentheroudakis, J. Ahlgren, D. Smith, A. Valachis
Journal: Annals of Oncology (2024)
94P A one-tube multiplex methylation-specific droplet digital PCR assay for identification of ctDNA biomarkers in anal squamous cell carcinoma
Authors: K-L. Spindler, S. Kahns, L.M. Canto, C.M. Jacobsen, J.S. Madsen, R. Steenbergen, B.M. Havelund, T.F. Hansen, A.K. Jakobsen, R.F. Andersen
Journal: Annals of Oncology (2024)
114P Prevalence and landscape of pathogenic or likely pathogenic germline variants in cancer predisposition genes among selected patients with lung adenocarcinoma
Authors: O.G. Arrieta Rodriguez, E. Caballe Perez, N.Y. Hernandez-Pedro, E. Romero, J. Lucio-Lozada, C. Castillo-Ruiz, K. Acevedo-Castillo, R.M. Álvarez-Gómez, C. Molina-Garay, M. Jiménez-Olivares, K. Carrillo-Sánchez, E.C. Mendoza-Caamal, A.F. Cardona Zorrilla, J. Remon Masip, C. Alaez-Verson
Journal: Annals of Oncology (2024)
129P Integrating large data to unveil vulnerabilities for patients with hot tumors resistant to checkpoint inhibition
Authors: A. Li, Z. Yu, K. Chen, Q. Zhang, W. Zhuang, X. Yang, Y. Ma, R. Hu, M. Shi, Z. Tan, Y-H. Zhou, L. Luo, S. Zhao, Y. Yang, W.F. Fang, L. Zhang, Y. Zhou, S.D. Hong
Journal: Annals of Oncology (2024)
83P Circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) in eary high risk breast cancer: The CITUCEL trial update
Authors: R. Borea, B. Cardinali, L. Arecco, G. De Luca, A. Garuti, C. Mazzitelli, A. Sciutto, F. Poggio, B. Conte, G. Buzzatti, E. Blondeaux, F. Carli, G. Anselmi, A. Profumo, G.F. Coronel-Vargas, A. Ballestrero, L. Ferrando, G. Zoppoli, M. Dono, L. Del Mastro
Journal: Annals of Oncology (2024)
85P True single-circulating tumor cell genomics reveals enriched therapy-resistance signatures in advanced colorectal cancer patients
Authors: M. Dongare, G. Shafi, A. Bharde, S. Andhari, G. Khutale, K. Hariramani, M. Basavalingegowda, A. Ramesh, V. Jadhav, M. Uttarwar, J. Khandare
Journal: Annals of Oncology (2024)
99P Circulating tumor DNA as a biomarker for neratinib and trastuzumab efficacy in HER2-mutated advanced solid tumors: Insights from KCSG AL20-17/KM23 phase II trial
Authors: K. Lee, K-H. Lee, D-W. Kim, J.S. Yoon, W. Choi, Y. Lee, Y.J. Choi, S. Lee, J.W. Kim, H. Ryu, D-H. Koo, Y-G. Lee, H-C. Jeung, M-Y. Lee, N. Lee, M.J. Kang, J. Lee, S-H. Hong, E.J. Kang, I.H. Park
Journal: Annals of Oncology (2024)
107P Germline pathogenic variants identified in tissue- and blood-based whole exome sequencing in advanced solid tumors
Authors: T. Kuwata, Y. Nakamura, T. Fujisawa, M. Imai-Sumida, S. Kadowaki, M. Ueno, S. Boku, N. Nonomura, E. Oki, M. Radovich, M. Aitani, C. Tomozawa, Y. Hiraoka, K. Kimura, S. Kosugi, I. Imoto, M. Hirata, T. Yoshino
Journal: Annals of Oncology (2024)
155P The molecular basis of the lymphocyte stability index (LSI): A pan-cancer peripheral biomarker for survival post immune checkpoint blockade (ICB)
Authors: R. Watson, O. Tong, M. Little, D. Muldoon, S. Mackay, A-A. Oluwafemi, S. Sun, G. Milotay, C. Taylor, G. Vallance, B. Shine, M.R. Middleton, N.A. Coupe, M. Payne, B.P. Fairfax
Journal: Annals of Oncology (2024)
162P Exploiting gp100-specific antibodies isolated from immune checkpoint inhibitor-responsive melanoma patients to target tumor cells
Authors: L. Flatz, T. Sinnberg, P. Li, O.T. Pop, K. Hofmeister, H. Niessner, A. Nuebling, M-T. Purde, A-K. Jochum, S. Forchhammer, C. Collins, B. Balciunaite, L. Risch, U. Leiter-Stoppke, A. Forschner, T.M.S. Amaral, R. Dummer, M.P. Levesque, M. Joerger, T. Etterlin
Journal: Annals of Oncology (2024)
153P 23ME-01473, an Fc-enhanced anti-ULBP6/2/5 antibody, restores anti-tumor NK cell function through NKG2D and FcgRIIIa activation
Authors: K. Gerrick, A. Jarret, C. Hom, A.N. Diep, S. Shi, P. Sood, J. Benjamin, S. Yadav, D. Ayupova, I-L. Chen, D. Kellar, C. Bonnans, P. Koenig, M. Poggio, G. Fuh, M. Schmidt
Journal: Annals of Oncology (2024)
305P Prognosis of isolated locoregional recurrence after early breast cancer with immediate breast reconstruction surgery: A retrospective multi-institutional study
Authors: H. Seki, A. Ogiya, N. Nagura, A. Shimo, K. Narui, S. Sasada, M. Ishitobi, H. Nogi, N. Kondo, T. Sakurai, C. Yamauchi, H. Mori, M. Saiga, N. Niikura, T. Shien
Journal: Annals of Oncology (2024)
468P Real-world safety of trametinib monotherapy or in combination with dabrafenib in children, adolescents, and young adults with relapsed or refractory low-grade glioma (LGG) and high-grade glioma (HGG)
Authors: N. Taleb, L.A. Ndounga-Diakou, S. Abbou, P. Leblond, I. Aerts, F. Sevrin, S. Ducassou, N. André, N. Entz-Werle, P. Chastagner, D. Plantaz, M. Gambart, C. Puiseux, C. Khanfar, S. Thouvenin, P. Schneider, G. Vassal, P. Berlanga, S. Laghouati
Journal: Annals of Oncology (2024)
257P Spatial predictors of pathologic complete response to neoadjuvant chemotherapy using imaging mass cytometry in the IMMUcan TNBC cohort
Authors: A.J. Garcia, M. Rediti, M. Morfouace, D. Venet, N. Eling, D. Schulz, M. Daniel, S. Déglise, B. Palau Fernandez, B. Bodenmiller, R. Liechti, F. Marzetta, N. Penel, J. Oliveira, J-C. Goeminne, P. Fournel, H.S. Hong, M. Cesaroni, C. Sotiriou, L. Buisseret
Journal: Annals of Oncology (2024)
157P Soluble and EV-bound CD27 act as antagonistic biomarkers in patients with solid tumors undergoing immunotherapy
Authors: J. Gorgulho, S.H. Loosen, R. Masood, G. Buescher, L. Kochheise, C. Schmidt, K. Schulze, M. Sinn, B. Fritzsche, M. Altfeld, S. Peine, H. Wikman, S. Huber, A.W. Lohse, F. Beier, T.H. Brümmendorf, C. Bokemeyer, T. Lüdde, J. Von Felden
Journal: Annals of Oncology (2024)
96P A novel strategy for single-nucleus RNA-seq of frozen PAXgene blood: A clinical alternative to single-cell RNA-seq of cryopreserved PBMCs
Authors: A. Rotem, O. Chaudhary, G. Duclos, P. Gathungu, M. Rao, R. Aguilar, L. Amir-Zilberstein, V. Shankarappa, C. Rands, X. Chen, E. Galery Harbolick, R. Halpin, M. Steinberg, J. Boland, M. Scaltriti, B. Dougherty
Journal: Annals of Oncology (2024)
154P Phase II study of nivolumab and relatlimab utilizing single cell analysis of circulating T cells reveals immune features associated with response to dual PD-1 and LAG-3 inhibition
Authors: J.J. Dollar, C. Decatur, S. Salazar, N. Cetta, J. Huuhtanen, C. Estevez, A. Cruz, M. Durante, S. Mustjoki, Z. Correa, J.W. Harbour, J. Lutzky
Journal: Annals of Oncology (2024)
112P Reporting of molecular test results from cell-free DNA analyses: Expert consensus recommendations from the 2023 European Liquid Biopsy Society ctDNA workshop
Authors: V.D. de Jager, P. Giacomini, J. Fairley, R.D.A. Toledo, S. Patton, S. Joosse, C. Koch, S. Deans, E. Heitzer, E. Schuuring
Journal: Annals of Oncology (2024)
458P Patterns of care and clinical outcomes of patients with glioblastoma in the United States from 2005-2020: A real-world analysis
Authors: D. Jayram, S. Bellur, A. Ozair, S. Ahmad, L. Hodgson, N. Frias Perez, V. Podder, M.A. Ganiyani, M. Ahluwalia
Journal: Annals of Oncology (2024)
91P Ultra-sensitive ctDNA NGS assay enhances genomic profiling for advanced HR-positive, HER2-negative breast cancer on endocrine therapy
Authors: H. Liao, J. Zhong, X-R. Liu, B. Shao, H. Tang, C. Jia, F. Xie, Y. Zhang, S. Jia, H. Li
Journal: Annals of Oncology (2024)
119P Predicting the pathogenicity of novel fusion genes and explaining reasons using a large language model: A focused assessment
Authors: K. Murakami, S-I. Tago, S. Takishita, H. Morikawa, R. Kojima, S. Abe, K. Yokoyama, M. Ogawa, H. Fukushima, H. Takamori, Y. Nannya, S. Imoto, M. Fuji
Journal: Annals of Oncology (2024)
161P Fibroblast activation protein (FAP)-CD40 (RO7300490) mediates intratumoral DC maturation and modulation of the tumor microenvironment
Authors: I. Melero, B. Reis, M.J. Lostes Bardaji, I. Spanggaard, D.H. Lee, J. Spicer, F. Thistlethwaite, S.N. Symeonides, D-Y. Oh, A. Hollebecque, N. Rieder, P. Schwalie, S. Badillo, N. Kumpesa, A. Thommen, C. Rusterholz, O. Cirovic, G. Kazantzidis, V. Moreno Garcia, A. Epp
Journal: Annals of Oncology (2024)
355P EVERolimus effectiveness after proGREssion on CDK4/6 inhibitors for ENdocrine receptor-positive/HER2-negative, advanced breast cancer: EVERGREEN quasi-experimental study
Authors: S.L. Lobo-Martins, D. Martins Branco, P.G. Aftimos, B.A. Pereira, A.L.V. Matos, L.M. Raposo Fernandes, E.F. Reis Campoa, G. Nader Marta, M. Moreau, T. Donatienne, F.P. Duhoux, P. Simões, A.R. Meira Garcia, V.D.C. Patel, C. Confente, D. Alpuim Costa, J.R. Pereira, C. Santos, L. Ameye, E. de Azambuja
Journal: Annals of Oncology (2024)
156P Microbiota-related multiomics to assess the clinical relevance of antibiotics (ATB) in immunotherapy (ICI)
Authors: A. Bonato, L. Belluomini, G. Vitali, A. Almonte, E. Menu, F. Gattazzo, R. Birebent, C. Parisi, D. Planchard, N. Naoun, R. Flippot, L. Albiges, Y. Loriot, B. Besse, S. Ranque, J. Remon Masip, C. Alves Costa Silva, F. Barlesi, L. Zitvogel, L. Derosa
Journal: Annals of Oncology (2024)